Kyverna Therapeutics (KYTX) Stock Forecast & Price Target

$5.32

+0.20 (+3.91%)

(As of 10/28/2024 ET)

Kyverna Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 9 Analyst Ratings

Sell
0

Hold
1

Buy
8

Based on 9 Wall Street analysts who have issued ratings for Kyverna Therapeutics in the last 12 months, the stock has a consensus rating of "Buy." Out of the 9 analysts, 1 has given a hold rating, 7 have given a buy rating, and 1 has given a strong buy rating for KYTX.

Consensus Price Target

$28.71
439.74% Upside

According to the 9 analysts' twelve-month price targets for Kyverna Therapeutics, the average price target is $28.71. The highest price target for KYTX is $48.00, while the lowest price target for KYTX is $7.00. The average price target represents a forecasted upside of 439.74% from the current price of $5.32.

KYTX Analyst Ratings Over Time

Type	Current Forecast 10/29/23 to 10/28/24	1 Month Ago 9/29/23 to 9/28/24	3 Months Ago 7/31/23 to 7/30/24	1 Year Ago 10/29/22 to 10/29/23
Strong Buy	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	N/A
Buy	7 Buy rating(s)	5 Buy rating(s)	5 Buy rating(s)	N/A
Hold	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)	N/A
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	N/A
Consensus Price Target	$28.71	$34.40	$35.80	N/A
Forecasted Upside	439.74% Upside	557.74% Upside	309.14% Upside	N/A
Consensus Rating	Buy	Moderate Buy	Moderate Buy	N/A

625,000% Gain (Ad)

Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.

>> Dive into the Workshop Here

KYTX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

KYTX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Kyverna Therapeutics Stock vs. The Competition

Type	Kyverna Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.79	2.50
Consensus Rating	Buy	Moderate Buy	Hold
Predicted Upside	460.83% Upside	34,207.69% Upside	9.18% Upside
News Sentiment Rating	Positive News See Recent KYTX News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
10/10/2024	UBS Group 4 of 5 stars	T. Huynh Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$13.00	+188.25%
10/9/2024	RODMAN&RENSHAW 0 of 5 stars	T. Butler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
10/9/2024	Rodman & Renshaw 1 of 5 stars		Initiated Coverage	Buy	$16.00	+247.83%
9/19/2024	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Kapoor Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$7.00 ➝ $7.00	+6.06%
7/31/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$39.00 ➝ $33.00	+282.83%
3/4/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	T. Smith Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
3/4/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Overweight	$44.00	+58.56%
3/4/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$48.00	+72.97%
3/4/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Overweight	$40.00	+44.14%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 06:22 PM ET.

KYTX Forecast - Frequently Asked Questions

: According to the research reports of 9 Wall Street equities research analysts, the average twelve-month stock price forecast for Kyverna Therapeutics is $28.71, with a high forecast of $48.00 and a low forecast of $7.00.
: 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kyverna Therapeutics in the last twelve months. There is currently 1 hold rating, 7 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" KYTX shares.
: According to analysts, Kyverna Therapeutics's stock has a predicted upside of 439.74% based on their 12-month stock forecasts.
: Over the previous 90 days, Kyverna Therapeutics's stock had 1 upgrade by analysts.
: Kyverna Therapeutics has been rated by research analysts at HC Wainwright, JPMorgan Chase & Co., Rodman & Renshaw, RODMAN&RENSHAW, and UBS Group in the past 90 days.
: Analysts like Kyverna Therapeutics more than other "medical" companies. The consensus rating for Kyverna Therapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how KYTX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

[625,000% Gain] – Are You Ready for the Next Altcoin Boom? (Ad)

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

This page (NASDAQ:KYTX) was last updated on 10/28/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kyverna Therapeutics (KYTX) Stock Forecast & Price Target